Aura Biosciences Inc. Common Stock (AURA)

FairStock Score: 37/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Mr. Market is offering Aura at $6.27 as of 2026-10-13, valuing the whole enterprise at $650.2M. I see a clinical-stage biotechnology company of 113 employees, with no revenue and no profits. The filed record shows net losses of $76.4M in FY2023, $86.9M in FY2024, and $106.2M in FY2025. In fiscal Q1 2026, the quarter ended 2026-03-31, the company lost $33.7M; in fiscal Q2 2026, the quarter ended 2026-06-30, it lost $45.6M. That is not a business with an earnings moat; it is a research pipeline consuming capital. FairStock's trailing free cash flow is -$103.4M, a -15.9% FCF yield, and the P/E at the close is -3.62. P/B is 2.06, but with ROE of -53.49% and ROCE of -31.24%, book value is not producing a return. The Piotroski F-Score is 2/9, and the Lynch category is none because losses occurred in each of the last four years. On the positive side, D/E is 0.05 and the Altman Z-Score is 10.69 by FairStock's calculation, so debt is not the immediate danger; cash burn and clinical uncertainty are. The lead candidate, bel-sar, is in late-stage development for primary choroidal melanoma and other ocular oncology indications. If it works, the payoff could be large. But Graham would ask for demonstrable earning power and a margin of safety. Here, value rests on binary trial outcomes, not on present numbers. I would watch the losses, cash use, and trial progress closely.

In plain English: Aura Biosciences is a small medical research company trying to develop precision therapies for solid tumors, especially an eye cancer treatment called bel-sar. It has no revenue and has lost money in each of the last four years, so the business looks financially weak today, though it carries little debt. At the 2026-10-13 closing price of $6.27, the stock is not cheap based on current profits or sales because there are none; its value depends almost entirely on future trial success.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer